Literature DB >> 6705133

Radioactive species in rat urines and tissues after [14C] AD 32 administration.

G Zini, G P Vicario, M Lazzati, F Arcamone.   

Abstract

[14-14C]N-Trifluoroacetyldoxorubicin-14-valerate [( 14C]AD 32) was synthesized and administered IV to male rats at 9.09 mg/kg. Urinary radioactivity excreted in the 0-24 h interval was only 2.3% of the dose, N-trifluoroacetyldoxorubicin (AD 41), 13-dihydro-N-trifluoroacetyldoxorubicin (AD 92), and doxorubicin being the major urinary metabolites identified. Doxorubicin and AD 32 were the main radioactive species extracted from tissues at 24 h after treatment. The amount of doxorubicin present in the analysed tissue samples is in agreement with the relatively low toxicity of AD 32 compared with doxorubicin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6705133     DOI: 10.1007/bf00256537

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

1.  Synthesis of [14-14C] daunorubicin and doxorubicin.

Authors:  S Penco; G Vicario; F Angelucci; F Arcamone
Journal:  J Antibiot (Tokyo)       Date:  1977-09       Impact factor: 2.649

2.  A fluorometric assay for daunomycin and adriamycin in animal tissues.

Authors:  H S Schwartz
Journal:  Biochem Med       Date:  1973-06

3.  The isolation of morphine ethereal sulfate from urine of the chicken and cat.

Authors:  J M Fujimoto; V B Haarstad
Journal:  J Pharmacol Exp Ther       Date:  1969-01       Impact factor: 4.030

4.  Antitumor activity of N-trifuloroacetyladriamycin-14-valerate.

Authors:  G Pratesi; A M Casazza; A Di Marco
Journal:  Cancer Treat Rep       Date:  1978-01

5.  Urinary anthracycline metabolites from mice treated with adriamycin and N-trifluoroacetyladriamycin-14-valerate.

Authors:  M Israel; W J Pegg; P M Wilkinson
Journal:  J Pharmacol Exp Ther       Date:  1978-03       Impact factor: 4.030

6.  Distribution of radioactivity and anthracycline-fluorescence in tissues of mice one hour after [14C]-labeled AD 32 administration. Evidence for tissue aglycone formation.

Authors:  M Israel; A M Karkowsky; V K Khetarpal
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

7.  Differences in cellular uptake and cytofluorescence of adriamycin and N-trifluoroacetyladriamycin-14-valerate.

Authors:  A Krishan; M Israel; E J Modest; E Frei
Journal:  Cancer Res       Date:  1976-06       Impact factor: 12.701

8.  Hepatobiliary metabolism and excretion of adriamycin and N-trifluoroacetyladriamycin-14-valerate in the rat.

Authors:  M Israel; P M Wilkinson; W J Pegg; E Frei
Journal:  Cancer Res       Date:  1978-02       Impact factor: 12.701

9.  Disposition of 14C-labelled 4'-epidoxorubicin and doxorubicin in the rat. A comparative study.

Authors:  F Arcamone; M Lazzati; G P Vicario; G Zini
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

10.  N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin.

Authors:  M Israel; E J Modest; E Frei
Journal:  Cancer Res       Date:  1975-05       Impact factor: 12.701

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.